X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (251) 251
Publication (26) 26
Book / eBook (13) 13
Newspaper Article (11) 11
Book Chapter (2) 2
Dissertation (2) 2
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (112) 112
humans (111) 111
oncology (111) 111
female (100) 100
breast cancer (86) 86
breast neoplasms - drug therapy (77) 77
trastuzumab (70) 70
chemotherapy (58) 58
middle aged (45) 45
breast neoplasms - pathology (44) 44
cancer (43) 43
adult (39) 39
antineoplastic combined chemotherapy protocols - therapeutic use (34) 34
chemotherapy, adjuvant (34) 34
adjuvant chemotherapy (32) 32
aged (32) 32
antineoplastic agents - therapeutic use (32) 32
disease-free survival (31) 31
treatment outcome (31) 31
open-label (29) 29
care and treatment (26) 26
breast neoplasms - mortality (23) 23
analysis (22) 22
prognosis (22) 22
antineoplastic agents - adverse effects (21) 21
breast neoplasms - metabolism (21) 21
lapatinib (21) 21
breast neoplasms - genetics (20) 20
patients (20) 20
therapy (20) 20
antibodies, monoclonal, humanized (19) 19
hematology, oncology and palliative medicine (19) 19
receptor, erbb-2 - metabolism (19) 19
research (19) 19
survival (19) 19
women (19) 19
tumors (18) 18
clinical trials (17) 17
neoplasm staging (17) 17
receptor, erbb-2 - antagonists & inhibitors (17) 17
cancer therapies (16) 16
erbb-2 protein (16) 16
health aspects (16) 16
paclitaxel (16) 16
receptor, erbb-2 - analysis (16) 16
risk factors (16) 16
adjuvant treatment (15) 15
antineoplastic combined chemotherapy protocols - adverse effects (15) 15
neoadjuvant therapy (15) 15
surgery (15) 15
antibodies, monoclonal, humanized - administration & dosage (14) 14
breast neoplasms - chemistry (14) 14
antibodies, monoclonal - therapeutic use (13) 13
clinical trials as topic (13) 13
drug administration schedule (13) 13
metastasis (13) 13
plus (13) 13
quinazolines - administration & dosage (13) 13
anthracyclines (12) 12
antineoplastic agents - administration & dosage (12) 12
biomarkers, tumor - analysis (12) 12
cardiotoxicity (12) 12
her2 (12) 12
receptor, erbb-2 - genetics (12) 12
1506 (11) 11
antibodies, monoclonal, humanized - adverse effects (11) 11
breast neoplasms - therapy (11) 11
drug therapy (11) 11
endocrine therapy (11) 11
medicine & public health (11) 11
multicenter (11) 11
review (11) 11
survival analysis (11) 11
antibodies, monoclonal, humanized - therapeutic use (10) 10
antimitotic agents (10) 10
antineoplastic agents (10) 10
breast (10) 10
cyclophosphamide (10) 10
efficacy (10) 10
follow-up studies (10) 10
her2-positive breast-cancer (10) 10
metastatic breast-cancer (10) 10
obstetrics & gynecology (10) 10
randomized controlled trials as topic (10) 10
retrospective studies (10) 10
skin and connective tissue diseases (10) 10
toxicity (10) 10
biomarkers, tumor - metabolism (9) 9
cancer patients (9) 9
follow-up (9) 9
internal medicine (9) 9
pertuzumab (9) 9
postmenopausal women (9) 9
quinazolines - adverse effects (9) 9
quinazolines - therapeutic use (9) 9
trastuzumab - administration & dosage (9) 9
animals (8) 8
antibodies, monoclonal - adverse effects (8) 8
diagnosis (8) 8
epidermal growth factor (8) 8
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Oncologist, ISSN 1083-7159, 11/2019, Volume 24, Issue 11, pp. e1034 - e1043
Cardiac monitoring is becoming an important part of breast cancer care. Breast cancer and cardiovascular disease (CVD) share many common risk factors, and it... 
Metastatic breast cancer | Cardio‐oncology | Cardiac monitoring | Cardiac dysfunction
Journal Article
Oncotarget, ISSN 1949-2553, 01/2019, Volume 10, Issue 9, pp. 926 - 929
A complete oncofertility counselling should be offered to all premenopausal patients before the administration of anticancer treatments. This important... 
Breast cancer | Lapatinib | HER2 | Fertility | Trastuzumab
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. 10068 - 10068
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2017, Volume 377, Issue 2, pp. 122 - 131
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10075, pp. 1195 - 1205
Journal Article
ecancermedicalscience, ISSN 1754-6605, 10/2016, Volume 10, p. 681
The use of unproven forms of therapy in cancer treatment is very common. In Brazil, the distribution by researchers to patients of an investigational agent... 
Brazil | Science | Ethics | Phosphoethanolamine | Cancer | Drugs | Medical research | Decision making | Oncology | Patients | Cancer therapies | Public health
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 03/2009, Volume 15, Issue 6, pp. 1848 - 1852
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9816, pp. 633 - 640
Summary Background The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and... 
Internal Medicine | ADJUVANT CHEMOTHERAPY | APOPTOSIS | CELLS | WOMEN | MEDICINE, GENERAL & INTERNAL | GW572016 | ERBB2 | INHIBITOR | PLUS | Breast Neoplasms - surgery | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Diarrhea - chemically induced | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Liver - drug effects | Adult | Female | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Paclitaxel - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Liver - metabolism | Paclitaxel - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Quinazolines - adverse effects | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Drug therapy | Breast cancer | Genetic aspects | Ultrasonic imaging | Surgery | Diarrhea | Cytotoxicity | Ligands | Cancer therapies | Tumors | Medical research | Mammography | Kinases | pathology | Liver | methods | Antibodies | Oral | Quinazolines | Breast Neoplasms | Tumor Markers | administration & dosage | Paclitaxel | Neoadjuvant Therapy | Adjuvant | Monoclonal | chemistry | Administration | drug therapy | chemically induced | Intravenous | Infusions | Humanized | Antineoplastic Combined Chemotherapy Protocols | drug effects | Biological | analysis | Kirurgi | antagonists & inhibitors | Chemotherapy | Receptor | adverse effects | metabolism | Cancer and Oncology | therapeutic use | Cancer och onkologi | erbB-2
Journal Article
Current opinion in oncology, 10/2018
This manuscript aims at providing an updated overview on the role of adding ovarian function suppression to tamoxifen or an aromatase inhibitor as adjuvant... 
Journal Article
Future oncology (London, England), 04/2019
Although the prognosis of HER2-positive breast cancer patients has dramatically improved with modern chemotherapy and the monoclonal antibody trastuzumab, up... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2017, Volume 35, Issue 18_suppl, pp. LBA500 - LBA500
LBA500 Background: In previous trials P significantly prolonged progression free and overall survival and increased pCR rates when added to T+C in pts with... 
Journal Article